US20070190185A1 - Plant extract mixtures and their uses - Google Patents
Plant extract mixtures and their uses Download PDFInfo
- Publication number
- US20070190185A1 US20070190185A1 US11/464,469 US46446906A US2007190185A1 US 20070190185 A1 US20070190185 A1 US 20070190185A1 US 46446906 A US46446906 A US 46446906A US 2007190185 A1 US2007190185 A1 US 2007190185A1
- Authority
- US
- United States
- Prior art keywords
- chitosan
- fecal
- vernonia
- cissus
- fat
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/19—Acanthaceae (Acanthus family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present disclosure is directed to the use of plant extracts from one or more plants of the Cissus, Vernonia and Brillantasia plant families to provide a variety of health related benefits, including but not limited to, enhancing fat-binding capacity, inhibiting carbohydrate breakdown, inhibiting amylase activity and/or improving nutrient absorption in the presence or absence of fat binding materials.
- the present disclosure is also directed to the use of mixtures comprising plant extracts from plants in at least one of three families (one or more of Cissus, Vernonia and Brillantasia ) to enhance fat-binding capacity as well as the inhibition of carbohydrate breakdown, amylase activity and nutrient absorption in the presence of fat binding materials.
- the mixtures can be combined with chitosan or chitosan derivatives to synergize their fat binding properties.
- Fat binding materials e.g. chitosan have applications in industry and in health. In both cases, the binding capacity of these materials is limited because of their bulk.
- the new combination of plant extracts has the ability to enhance the fat binding capacity of such materials as well as alter the metabolism of other compounds in animals, including humans.
- Chitosan is widely used for the control of weight. Its use is based on its ability to bind fatty acids in vitro and in vivo, thereby reducing the ability of the body to absorb and utilize dietary fats.
- chitosan By combining chitosan with two plant extracts; Cissus quadrangularis and Vernonia glabra, its ability to bind fatty acids and triacylglycerols in vitro was significantly increased (p ⁇ 0.05 and p ⁇ 0.01 respectively). This is reflected in the significantly higher fat content of the feces of subjects on chitosan or chitosan based formulations.
- the combination of chitosan and Cissus quadrangularis significantly increased the fecal pH (p ⁇ 0.01), fecal ash (p ⁇ 0.02) and mineral content (p ⁇ 0.02) in overweight women (BMI 25-29 kg/m 2 ) over a six month period, while decreasing the fecal water content (p ⁇ 0.01).
- the combination of chitosan and Vernonia glabra did not alter the mineral content or the pH of the feces although it caused a significant increase (p ⁇ 0.05) in fecal bulk. The results indicate that the chitosan and Vernonia glabra combination can be effectively used in long term weight control regimes.
- Chitosan is a polysaccharide produced from chitin found in the exoskeletons of arthropods (crustaceans and insects) and the endoskeletons of cephalopods. It is widely spread in the biomass, being the most abundant biopolymer after cellulose. It is generally accepted that chitin is extensively acetylated while chitosan is largely deacetylated. Chitosan is a cationic glucosamine polymer with a high anion-exchange capacity as a result of quaternary ammonium ions. It is known to have a marked hypocholesterolemic effect in rats, alters bile acid metabolism and increases the HDL to total cholesterol ratio in broiler chickens. The hypocholesterolemic effect of chitosan can be theoretically explained by its ability to decrease lipid absorption and increase fecal cholesterol excretion. The alteration of bile acid can be due to the modification of colon pH.
- Chitosan is widely used in weight control products. Its application is a result of its ability to bind triglycerides in vitro. In principle therefore, chitosan limits the amount of fat energy that can be absorbed and used by the body. The use of chitosan therefore does not find application only as a weight loss supplement, but also as a means of reducing blood lipids.
- the present disclosure is directed to the use of plant extracts from one or more plants of the Cissus, Vernonia and Brillantasia plant families to provide a variety of health related benefits, including but not limited to, enhancing fat-binding capacity, inhibiting carbohydrate breakdown, inhibiting amylase activity and/or improving nutrient absorption in the presence or absence of fat binding materials.
- the present disclosure is also directed to the use of mixtures comprising plant extracts from plants in at least one of three families (one or more of Cissus, Vernonia and Brillantasia ) to enhance fat-binding capacity as well as the inhibition of carbohydrate breakdown, amylase activity and/or nutrient absorption in the presence of fat binding materials.
- the mixtures can be combined with chitosan or chitosan derivatives to synergize their fat binding properties.
- FIG. 1 is a bar graph displaying the results of experiments measuring the effect thirty days of supplementation with an exemplary chitosan formulation had on total fecal lipid excretion.
- compositions comprising extract of one or more plants of one or more of the following plant families: Cissus, Vernonia and Brillantasia.
- the invention provides uses of such compositions in treating disease or disorder, in particular for preventing, controlling or combating obesity.
- the invention provides such compositions for the preparation of a medicament for use in treating any of the ailments or conditions herein described.
- the composition comprises or consists of a mixture of at least two of the said plant extracts.
- the composition also includes one or more fat binding materials such as chitosan or a chitosan derivative.
- the composition also includes one or more amylase inhibiting compounds and/or one or more antioxidants such as vitamins A, C, or E.
- the plant extracts are usefully obtained from dried or freeze dried plant components.
- the extract may be of the leaves, roots and/or stem of the plants.
- the extract may be dried powder or entirely aqueous-derived such extract, e.g. obtained by boiling the plant components in water, or derived from a mixture containing water and, for example, ethanol. A mixture of water and 50% by volume of ethanol is suitable and preferred.
- the extracts are also preferably ion exchange unbound and resin scavenged prior to use and formulation with chitosan or chitosan derivative. It is possible, but less preferred to use extracts derived from the solvent dichloromethane.
- the plant components used in making the extract are the leaves, roots and/or stem.
- the extracts are aqueous and can be produced by a simple, conventional extraction technique, although it is more preferable that the plant components be dried before addition of water and boiling the mixture.
- compositions can be formulated for human consumption and demonstrate one or more of the following other properties:
- Plant Component Used Leaves, Stems and Roots
- Preparation method The leaves, stems and roots are dried at 45° C. for 72 hours. The dried samples are transferred into 2 times their weight of water and boiled for 1 hour. The mixture is left to stand for 2 hours at room temperature before straining to remove any residue. The resultant supernatant is stored at 4° C. until required.
- Preparation method The leaves are harvested from the plant and dried at 45° C. for 72 hours. The dried leaves are finely ground into a powder, then transferred into 2 times their weight of boiling water. This is left to stand for two hours at room temperature before straining to remove leaf residue. The resultant supernatant was stored at 4° C. until required.
- the mixture can be taken orally at a concentration of 0.1 to 10 ml, preferably 0.1 to 5 ml, more preferably 0.2 to 2 ml, most preferably 0.5 ml per kilogram body weight with or before a meal.
- Subjects were randomly allocated one of four treatments in a double blinded study. The results are for fifty nine subjects who completed the study.
- the control group received maize flour, while the other groups received either chitosan, chitosan plus Vernonia glabra (16% w/w) or chitosan plus Cissus quadrangularis (16% w/w). All subjects were required to consume 2 g of the control or test material twice daily before their main meals.
- Feces were collected for four consecutive days every other week, in special glass containers and brought daily to the laboratory for storage. All subjects were instructed to bring in their samples as soon as was possible. The feces was weighed and the pH measured. An aliquot (2 g) of the feces was used for the determination of total lipid using the method described by Folch, et al. (1957). The dry matter weight was determined using a homogenate of the total feces collected (three days drying at 55° C.).
- Fecal ash was determined after 48 hours incineration at 500° C. Fecal calcium and magnesium was determined using the modified methods described by SIGMA company. In these methods, the ash was dissolved in nitric acid solution (3N) and the calcium and magnesium assayed spectrophotometrically using arsenazo dye III and calmagite respectively. Total nitrogen was determined by the Kjeldahl procedure. Statistical significance was determined using paired Student's t-test.
- the average energy and nutrient intake of subjects is given in Table 3. This is similar to the intake of that age group of women in Cameroon. TABLE 3 The mean of total energy, lipid, carbohydrate, protein, calcium, magnesium and fiber of subject dietary intake mean ⁇ SD ENERGY (Kcal/day) 2346.48 ⁇ 535.55 LIPID (g/day) 92.93 ⁇ 28.00 CARBOHYDRATE (g/day) 367.51 ⁇ 64.54 PROTEIN (g/day) 83.50 ⁇ 15.15 FIBER (g/day) 22.41 ⁇ 5.58 CALCIUM (mg/day) 421.78 ⁇ 243.98 MAGNESIUM (mg/day) 134.58 ⁇ 45.86
- Table 4 demonstrates the ability of chitosan to reduce pH, which is possibly as a result of the formation of glucosamine in the intestine. At this low pH, there is a modification of bile acid metabolism.
- the formulation containing Vernonia glabra however significantly (p ⁇ 0.05) increased the amount of nitrogen present in the feces (Table 6). This increase is still significant even when the amounts contributed by the presence of chitosan is taken into consideration.
- fecal nitrogen is significantly (p ⁇ 0.05) reduced by the chitosan formulation containing Cissus quadrangularis.
- Vernonia glabra therefore seems to play a role in inhibiting the absorption of nitrogenous compounds which will otherwise be favored by an increase in pH.
- Chitosan and chitosan based formulations containing Cissus quadrangularis and Vernonia glabra were administered to sixteen overweight (BMI>25 kg/m2) women on an energy restricted diet supplemented with vitamins and minerals over a period of eight months.
- BMI breast milk
- a significant reduction in the circulating levels of cholesterol and total triglycerides was observed in all the chitosan based groups.
- the subjects were given a number of possible diets they could follow, which provided a total daily energy intake of 1500 kcal.
- BMI Body Mass Index
- the BMI of subjects was measured using an electronic scale and a meter rule attached to the wall.
- the percentage body fat was determined by using bioelectrical impedance measurements.
- concentration of total cholesterol and triglycerides were determined using Sigma kits.
- Chitosan and the chitosan formulation containing Cissus quadrangularis were the most effective in lowering blood cholesterol levels for any given time point.
- Chitosan and chitosan formulations significantly decreased the circulating concentrations of triglycerides. This is as a result of their ability to bind triglycerides in vitro as well as in vivo. The presence of plant extracts did not seem to have a potentiating effect on the ability of chitosan to bind triglycerides.
- the mixture used in this part of the work had the following composition: Chitosan 61.8% Vitamin C 19.0% Vernonia glabra powder 5.7% Cissus quadrangularis powder 13.5%
- This mixture had a superior lipid binding capacity in vitro compared to other chitosan formulations containing either Vernonia glabra or Cissus quadrangularis.
- the chitosan formulation containing a mixture of Cissus quadrangularis and Vernonia glabra significantly reduced the BMI of overweight females faster than formulations containing either Cissus quadrangularis or Vernonia glabra.
- This synergistic effect is possibly as a result of a reduction in the available glucose substrate for use as a fuel ( ⁇ -amylase inhibition by Vernonia glabra ). Fat preferentially used as fuel.
- BMI Body mass index
- Human salivary amylase (Sigma A0521) and porcine pancreatic amylase (Sigma A3176) were used as starting material.
- the substrate used was starch and the formation of maltose was used to quantify and measure the activity of the amylase.
- One unit of activity of the mixture reduced the activity of salivary amylase by 50%, and the activity of pancreatic amylase by 65%.
- Laboratory animals were fed diets containing the mixture (0.5 ml/kg body weight) after an overnight fast.
- the content of their stomachs had a higher pH than control animals.
- Pancreatic Lipase (Sigma L9780) was used as starting material.
- One unit of the mixture is the quantity that will reduce the activity of 0.48 units of lipase by 50%. (One unit of lipase will liberate 1.0 ⁇ l of 2-monoglyceride from 1,2-diglyceride per minute at 37° C., pH 8.1).
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Fats And Perfumes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
A composition comprising extract of one or more plants of one or more of the following plant families: Cissus, Vernonia and Brillantasia. Such compositions have benefical activity principally in controlling weight gain and obesity, especially in conjunction with chitosan or a chitosan derivative and an antioxidant such as vitamin C.
Description
- This application is a continuation application of U.S. patent application Ser. No. 10/069,743, filed on Sep. 10, 2002, which claims the benefit of U.S. National Stage application number PCT/GB00/03324 under 35 U.S.C. §371, filed on Aug. 29, 2000, which claims benefit under 35 U.S.C. §119(a) to Great Britain Application No. 9920393.7, filed on Aug. 27,1999. These applications are incorporated herein by reference.
- The present disclosure is directed to the use of plant extracts from one or more plants of the Cissus, Vernonia and Brillantasia plant families to provide a variety of health related benefits, including but not limited to, enhancing fat-binding capacity, inhibiting carbohydrate breakdown, inhibiting amylase activity and/or improving nutrient absorption in the presence or absence of fat binding materials.
- The present disclosure is also directed to the use of mixtures comprising plant extracts from plants in at least one of three families (one or more of Cissus, Vernonia and Brillantasia) to enhance fat-binding capacity as well as the inhibition of carbohydrate breakdown, amylase activity and nutrient absorption in the presence of fat binding materials. In at least on embodiment the mixtures can be combined with chitosan or chitosan derivatives to synergize their fat binding properties.
- Fat binding materials e.g. chitosan have applications in industry and in health. In both cases, the binding capacity of these materials is limited because of their bulk. The new combination of plant extracts has the ability to enhance the fat binding capacity of such materials as well as alter the metabolism of other compounds in animals, including humans.
- Chitosan is widely used for the control of weight. Its use is based on its ability to bind fatty acids in vitro and in vivo, thereby reducing the ability of the body to absorb and utilize dietary fats. By combining chitosan with two plant extracts; Cissus quadrangularis and Vernonia glabra, its ability to bind fatty acids and triacylglycerols in vitro was significantly increased (p<0.05 and p<0.01 respectively). This is reflected in the significantly higher fat content of the feces of subjects on chitosan or chitosan based formulations. Compared to chitosan, the combination of chitosan and Cissus quadrangularis significantly increased the fecal pH (p<0.01), fecal ash (p<0.02) and mineral content (p<0.02) in overweight women (BMI 25-29 kg/m2) over a six month period, while decreasing the fecal water content (p<0.01). The combination of chitosan and Vernonia glabra did not alter the mineral content or the pH of the feces although it caused a significant increase (p<0.05) in fecal bulk. The results indicate that the chitosan and Vernonia glabra combination can be effectively used in long term weight control regimes.
- Chitosan is a polysaccharide produced from chitin found in the exoskeletons of arthropods (crustaceans and insects) and the endoskeletons of cephalopods. It is widely spread in the biomass, being the most abundant biopolymer after cellulose. It is generally accepted that chitin is extensively acetylated while chitosan is largely deacetylated. Chitosan is a cationic glucosamine polymer with a high anion-exchange capacity as a result of quaternary ammonium ions. It is known to have a marked hypocholesterolemic effect in rats, alters bile acid metabolism and increases the HDL to total cholesterol ratio in broiler chickens. The hypocholesterolemic effect of chitosan can be theoretically explained by its ability to decrease lipid absorption and increase fecal cholesterol excretion. The alteration of bile acid can be due to the modification of colon pH.
- Chitosan is widely used in weight control products. Its application is a result of its ability to bind triglycerides in vitro. In principle therefore, chitosan limits the amount of fat energy that can be absorbed and used by the body. The use of chitosan therefore does not find application only as a weight loss supplement, but also as a means of reducing blood lipids.
- The present disclosure is directed to the use of plant extracts from one or more plants of the Cissus, Vernonia and Brillantasia plant families to provide a variety of health related benefits, including but not limited to, enhancing fat-binding capacity, inhibiting carbohydrate breakdown, inhibiting amylase activity and/or improving nutrient absorption in the presence or absence of fat binding materials.
- The present disclosure is also directed to the use of mixtures comprising plant extracts from plants in at least one of three families (one or more of Cissus, Vernonia and Brillantasia) to enhance fat-binding capacity as well as the inhibition of carbohydrate breakdown, amylase activity and/or nutrient absorption in the presence of fat binding materials. In at least on embodiment of the present disclosure, the mixtures can be combined with chitosan or chitosan derivatives to synergize their fat binding properties.
- The above-mentioned features and objects of the present disclosure will become more apparent with reference to the following description taken in conjunction with the accompanying drawing.
-
FIG. 1 is a bar graph displaying the results of experiments measuring the effect thirty days of supplementation with an exemplary chitosan formulation had on total fecal lipid excretion. - We have investigated the effect of chitosan and chitosan based formulations on overweight women. Their BMI and body composition had been evaluated. The fecal weight, fecal pH, water content, calcium and magnesium content and total nitrogen were measured. The total blood lipid content and beneficial effects of plant supplements (extracts of Vernonia glabra and Cissus quadrangularis) on improved chitosan lipid binding has unexpectedly been found.
- According to one aspect of the present invention there is provided a composition comprising extract of one or more plants of one or more of the following plant families: Cissus, Vernonia and Brillantasia. According to another aspect the invention provides uses of such compositions in treating disease or disorder, in particular for preventing, controlling or combating obesity. In another aspect the invention provides such compositions for the preparation of a medicament for use in treating any of the ailments or conditions herein described.
- In at least one exemplary embodiment of the present disclosure, the composition comprises or consists of a mixture of at least two of the said plant extracts. In at least one other exemplary embodiment, the composition also includes one or more fat binding materials such as chitosan or a chitosan derivative. In at least one other exemplary embodiment, the composition also includes one or more amylase inhibiting compounds and/or one or more antioxidants such as vitamins A, C, or E.
- The plant extracts are usefully obtained from dried or freeze dried plant components. The extract may be of the leaves, roots and/or stem of the plants. The extract may be dried powder or entirely aqueous-derived such extract, e.g. obtained by boiling the plant components in water, or derived from a mixture containing water and, for example, ethanol. A mixture of water and 50% by volume of ethanol is suitable and preferred. The extracts are also preferably ion exchange unbound and resin scavenged prior to use and formulation with chitosan or chitosan derivative. It is possible, but less preferred to use extracts derived from the solvent dichloromethane.
- Preferably, in the case of plants of the Cissus family, the plant components used in making the extract are the leaves, roots and/or stem. Preferably the extracts are aqueous and can be produced by a simple, conventional extraction technique, although it is more preferable that the plant components be dried before addition of water and boiling the mixture.
- Such compositions can be formulated for human consumption and demonstrate one or more of the following other properties:
- (1) Reduces the amount of fat absorbed by the body,
- (2) Increases the amount of fat in feces,
- (3) Increases fecal bulk,
- (4) Reduces carbohydrate breakdown in vitro,
- (5) Reduces carbohydrate breakdown in vivo,
- (6) Inhibits salivary amylase activity,
- (7) Inhibits intestinal amylase activity,
- (8) Decreases the acidity of the stomach,
- (9) Increases the amount of cholesterol in feces,
- (10) Reduces post-prandial blood glucose,
- (11 ) Inhibits intestinal lipase activity,
- (12) Reduces the body mass index (weight) of subjects.
- Preparation of the Mixture: Plants of the Cissus family, Vernonia family, and Brillantasia family:
- Plant Component Used: Leaves, Stems and Roots
- Preparation method: The leaves, stems and roots are dried at 45° C. for 72 hours. The dried samples are transferred into 2 times their weight of water and boiled for 1 hour. The mixture is left to stand for 2 hours at room temperature before straining to remove any residue. The resultant supernatant is stored at 4° C. until required.
- Brillantasia sp.
- Plant Component Used: Leaves
- Preparation method: The leaves are harvested from the plant and dried at 45° C. for 72 hours. The dried leaves are finely ground into a powder, then transferred into 2 times their weight of boiling water. This is left to stand for two hours at room temperature before straining to remove leaf residue. The resultant supernatant was stored at 4° C. until required.
- Cissus sp. and Vernonia sp. Combination
- Although all combinations of extracts of plants of the three families, namely Cissus sp., Vernonia sp. and Brillantasia sp. had an enhancing effect, optimal activity was obtained using the following mixture of two aqueous plant extracts:
- Cissus sp. extract 50-90%, more preferably 60-80% most preferably 70% (v/v), Vernonia sp. 10-50% more preferably 20-40% most preferably 30% (v/v). This is a preferred specific mixture of Cissus sp. and Vernonia sp.
- Application and Dose
- The mixture can be taken orally at a concentration of 0.1 to 10 ml, preferably 0.1 to 5 ml, more preferably 0.2 to 2 ml, most preferably 0.5 ml per kilogram body weight with or before a meal.
- Plant materials: Vernonia glabra (root) and Cissus quadrangularis (leaf and stem) were harvested from the Western and Centre Provinces of Cameroon respectively. The plant material was washed and dried for three days in an oven at 55° C. The dried material was then ground, sieved and stored until required. Chitosan based formulations were made as show in Table 1 (increasing concentration of plant extract and decreasing chitosan content).
TABLE 1 Composition of different chitosan based formulations Constituents (mg) CF0 CF1 CF2 CF3 CF4 Chitosan 250 200 170 150 100 Vitamin C 60 60 60 60 60 Plant powder 0 50 80 100 150 - In vitro Binding Studies
- The ability of various chitosan combinations to bind triacylglycerol was carried out as described below. A specific weight (1-4 g) of chitosan or the chitosan combination was weighed out and incubated with shaking at 37° C. for 2 hours with 6 g soya oil and 10 ml hydrochloric acid (10 mmol/L). The acid was then neutralized and 10 ml phosphate buffered saline (pH 7.4) added. Incubation with shaking was continued for a further 3 hours at 37° C., after which the tubes were centrifuged at 2500 rpm for 30 min. Unadsorbed fat floated on the surface, was aspirated and weighed. This gave the amount of triacylglycerol not bound to the chitosan combination.
- Subjects
- Seventy four overweight (BMI 25-30 kg m2) women (19-32 years) were recruited to take part in the study. They gave their written consent after details of the trial had been verbally explained to them and could drop out of the study at anytime they wanted without having to give reason. Ethics approval was obtained from the Joint University/Ministry of Health Ethics committee, Cameroon.
- Subjects were randomly allocated one of four treatments in a double blinded study. The results are for fifty nine subjects who completed the study. The control group received maize flour, while the other groups received either chitosan, chitosan plus Vernonia glabra (16% w/w) or chitosan plus Cissus quadrangularis (16% w/w). All subjects were required to consume 2 g of the control or test material twice daily before their main meals.
- Diet
- The subjects were asked not to change their food habits and to maintain their normal diets as much as possible. They kept individual food diaries which were used to analyze food intake using food tables.
- Fecal Collections and Analysis.
- Feces were collected for four consecutive days every other week, in special glass containers and brought daily to the laboratory for storage. All subjects were instructed to bring in their samples as soon as was possible. The feces was weighed and the pH measured. An aliquot (2 g) of the feces was used for the determination of total lipid using the method described by Folch, et al. (1957). The dry matter weight was determined using a homogenate of the total feces collected (three days drying at 55° C.).
- Fecal ash was determined after 48 hours incineration at 500° C. Fecal calcium and magnesium was determined using the modified methods described by SIGMA company. In these methods, the ash was dissolved in nitric acid solution (3N) and the calcium and magnesium assayed spectrophotometrically using arsenazo dye III and calmagite respectively. Total nitrogen was determined by the Kjeldahl procedure. Statistical significance was determined using paired Student's t-test.
- Results
- In vitro Lipid Binding
- The in-vitro lipid binding of the different chitosan formulations is shown Table 2. The highest lipid binding was obtained with the formulation CF1 for each of the two plant powders containing 16% (w/w) of the plant. Cissus quadrangularis however bound more (P<0.001) lipid than Vernonia glabra (P<0.01). Other combinations containing Cissus quadrangularis enhanced the binding of soya oil. The binding was however not as high as for the CF1 combination containing 16% (w/w) plant powder.
TABLE 2 The effect of Chitosan formulations on in-vitro lipid (Soja oil) binding (g/g of Chitosan formulation). mean ± S.D Chitosan formulations Plant Powder CF0 CF1 CF2 CF3 CF4 V. glabra 13.70 ± 2.04 22.04 ± 17.81 ± 12.49 ± 10.44 ± 2.79** 4.09 4.78 4.9 C. quadrangularis 13.70 ± 2.04 27.80 ± 22.60 ± 18.03 ± 14.89 ± 0.47** 6.52** 1.17* 2.05
*P < 0.01
**P < 0.001
- Food Intake
- The average energy and nutrient intake of subjects is given in Table 3. This is similar to the intake of that age group of women in Cameroon.
TABLE 3 The mean of total energy, lipid, carbohydrate, protein, calcium, magnesium and fiber of subject dietary intake mean ± SD ENERGY (Kcal/day) 2346.48 ± 535.55 LIPID (g/day) 92.93 ± 28.00 CARBOHYDRATE (g/day) 367.51 ± 64.54 PROTEIN (g/day) 83.50 ± 15.15 FIBER (g/day) 22.41 ± 5.58 CALCIUM (mg/day) 421.78 ± 243.98 MAGNESIUM (mg/day) 134.58 ± 45.86 - Fecal Composition
- During the first week of the trial, only the formulation containing Vernonia glabra (16%, w/w) significantly (p<0.05) increased fecal wet weight as well as fecal dry weight (Table 4). On maintaining intake for a longer period (more than one month), chitosan (CFO) significantly reduced the fecal moisture content and increased (p<0.05) fecal pH, while the formulation containing Vernonia glabra significantly (p<0.05) reduced fecal pH.
- Table 4 demonstrates the ability of chitosan to reduce pH, which is possibly as a result of the formation of glucosamine in the intestine. At this low pH, there is a modification of bile acid metabolism.
- The reduction of fecal pH and moisture content noticed is reversed by the inclusion of Cissus quadrangularis.
- This study has shown a negative correlation between the fecal moisture and the fecal pH (r=−0.477) and even between fecal moisture and the root square of fecal pH[(pH)1/2] (r=−0.465), P<0.001. So the reduction of fecal moisture can be explained by the increase of the fecal pH.
- The reduction of fecal moisture is also dependent on the ash content since fecal moisture is negatively correlated to the fecal ash content (mg/g of FDW) (r=−0.301), P<0.01 (Table 5).
TABLE 5 Correlation between different fecal components Variable r(N = 80) Probability(P) moisture, pH −0.477 P < 0.001 moisture, (pH)1/2 −0.465 P < 0.001 moisture, ash −0.301 P < 0.01 ash, pH +0.248 P < 0.05 calcium, pH −0.221 P < 0.05 moisture, calcium +0.030 N.S ash, calcium −0.069 N.S pH, Nitrogen 0.232 P < 0.05 ash, Nitrogen +0.009 N.S moisture, Nitrogen +0.011 N.S - Chitosan as well as the chitosan formulation containing Cissus quadrangularis significantly (p<0.05) increased the fecal calcium concentration after one month of treatment (Table 6). The formulation containing Vernonia glabra however brought about a decrease in the concentration of fecal calcium. It is likely that the increased concentration of calcium in feces is as a result of contribution from the chitosan. There however seems to be a factor in the formulation containing Vernonia glabra that causes an increased retention of calcium.
- Unlike calcium, magnesium concentrations in the feces was not altered by any of the formulations (Table 6).
- Fermentation of chitosan in the large intestine produces glucosamine which can be absorbed (application in arthritis) by the body. Glucosamine can also bring about an increase in gut pH which favors the absorption of nitrogenous compounds (negative correlation between fecal pH and total fecal nitrogen, r=−0.232; p<0.05). The formulation containing Vernonia glabra however significantly (p<0.05) increased the amount of nitrogen present in the feces (Table 6). This increase is still significant even when the amounts contributed by the presence of chitosan is taken into consideration. On the other hand, fecal nitrogen is significantly (p<0.05) reduced by the chitosan formulation containing Cissus quadrangularis.
- Vernonia glabra therefore seems to play a role in inhibiting the absorption of nitrogenous compounds which will otherwise be favored by an increase in pH.
- Chitosan as well as chitosan based formulations significantly (p<0.01) increased the total amount of lipid in the feces (Table 7). This is as a result of the ability of chitosan to bind lipids in the gut. (It will however be interesting to investigate what happens to the mixture of lipids, chitosan and glucosamine in the large intestine).
- These results support the hypothesis that phytochemical substances in some plants can improve the ability of chitosan to bind lipids and contribute to weight loss without negatively altering the calcium and magnesium status of the subject.
- The results show that the chitosan only formulations increase fecal pH and cause constipation while CF1.V decreased the fecal pH. These results suggest that the long term intake of chitosan might cause colon cancer while the use of CF1.V can benefit overweight and obese patients.
TABLE 4 The effect of chitosan formulations on fecal wet and dry weight, pH and moisture Control (n = 20) Chitosan (n = 21) Chitosan + V.g (n = 18) Chitosan + C.q (n = 21) Measures D0 D>30 D0 D>30 D0 D>30 D0 D>30 Fecal wet 165.4 ± 26.4a 187.8 ± 41.5a 185.7 ± 24.6a 180.2 ± 16.7a 178.5 ± 39.0a 264.2 ± 33.0b 188.1 ± 28.6a 187.8 ± 82a weight (g/d) Fecal dry 26.3 ± 5.3a 28.5 ± 9.8a 29.0 ± 5.3a 28.9 ± 9.7a 28.2 ± 8.2a 36.0 ± 9.4b 28.2 ± 7.7a 27.2 ± 9.4a weight (g/d) Fecal moisture 79.8 ± 4.9a 80.1 ± 5.2a 78.6 ± 5.9a 72.6 ± 6.7b 79.1 ± 4.0a 81.0 ± 4.5a 78.9 ± 3.8a 74.9 ± 6.1ab % Fecal pH 6.9 ± 0.6a 6.8 ± 0.8ac 6.9 ± 0.4a 7.4 ± 0.3b 6.8 ± 0.2a 6.5 ± 0.3c 6.9 ± 0.5a 7.0 ± 0.3a
Values are 4-days means ± S.E.
Values without a common superscript are significantly different (P < 0.05)
-
TABLE 6 The effect of chitosan formulations on fecal ash, calcium and magnesium and nitrogen Control (n = 20) Chitosan (n = 21) Chitosan + V.g (n = 18) Chitosan + C.q (n = 21) Measures D0 D>30 D0 D>30 D0 D>30 D0 D>30 Fecal ash g/d 2.5 ± 1.1a 3.0 ± 0.9a 2.7 ± 1.4a 5.2 ± 3.7b 3.0 ± 1.3a 3.7 ± 1.8ab 2.8 ± 1.8a 5.4 ± 2.5b Calcium 100.1 ± 23.7a 117.6 ± 12.3a 104.4 ± 10.8a 180.3 ± 85.5b 88.4 ± 34.2ac 65.1 ± 15.2c 109.4 ± 15.3a 130.1 ± 14.3b mg/d Magnesium 83.5 ± 21.3a 76.5 ± 16.9a 89.6 ± 17.6a 100.5 ± 32.5a 82.3 ± 11.4a 89.4 ± 14.2a 91.1 ± 21.1a 92.5 ± 12.9a mg/d Nitrogen 354.5 ± 128.5a 384.3 ± 194.3a 391.7 ± 133.6a 421.7 ± 355.0a 379.9 ± 170.9a 1039.5 ± 540b 380.6 ± 164.5a 371.1 ± 196.4a (N2) mg/d N2- 354.5 ± 128.5a 384.3 ± 194.3a 391.7 ± 133.6a 312.9 ± 355.0a 379.9 ± 170.9a 930.7 ± 540.1b 380.6 ± 164.5a 371.1 ± 196.4c ChitosanN2 mg/d
Values are 4-days means ± S.E.
Statistical significance is by comparison within a specific measured parameter.
Values without a common superscript are significantly different (P < 0.05)
-
TABLE 7 The effect of chitosan formulations on total lipid excretion Control (n = 20) Chitosan (n = 21) Chitosan + V.g (n = 18) Chitosan + C.q (n = 21) Measures D0 D>30 D0 D>30 D0 D>30 D0 D>30 Total lipid (mg/g)a g/d 73 ± 15a 87 ± 15a 83 ± 16a 163 ± 18b 86 ± 19a 183 ± 12b 88 ± 16a 161 ± 6b 8.4 ± 3.7a 10.0 ± 4.0a 9.6 ± 4.1a 29.4 ± 14.2b 9.9 ± 4.5a 48.3 ± 9.2b 10.2 ± 3.9a 30.3 ± 13.2b
Values are 4-days means ± S.E.
Values without a common superscript are significantly different (P < 0.01)
- The effect of chitosan based formulations on body composition In overweight women.
- Chitosan and chitosan based formulations containing Cissus quadrangularis and Vernonia glabra were administered to sixteen overweight (BMI>25 kg/m2) women on an energy restricted diet supplemented with vitamins and minerals over a period of eight months. There was a significant reduction in the BMI of subjects given chitosan as well as the chitosan based formulations (4 grams per day) containing the plant extracts (16%, w/w), with the most significant reduction observed in subjects who received the chitosan based formulation containing Cissus quadrangularis. A significant reduction in the circulating levels of cholesterol and total triglycerides was observed in all the chitosan based groups.
- Materials and Methods
- The following combinations were used for the study:
- Group 1. Maize flour-Control group
- Group 2. Chitosan plus vitamin C
- Group 3. Chitosan plus vitamin C plus Vernonia glabra
- Group 4. Chitosan plus vitamin C plus Cissus quadrangularis
- Subjects
- Thirty two overweight(BMI>25 kg/M2) women (24-36 years) were recruited for the study. They gave their written consent after details of the trial had been verbally explained to them. They could drop out of the trial at any time without need to explain their action. The results reported are for twenty subjects who completed the study. Subjects randomly allocated one of the four treatments above in a double blind study. All subjects were required to consume 2 g of the control or test material twice daily before their main meals.
- Diet
- The subjects were given a number of possible diets they could follow, which provided a total daily energy intake of 1500 kcal.
- Body Mass Index (BMI) and Body Fat Content
- The BMI of subjects was measured using an electronic scale and a meter rule attached to the wall. The percentage body fat was determined by using bioelectrical impedance measurements.
- Blood Collection and Sampling
- Venous blood (20 ml) was collected from the forearm of subjects, and serum prepared from it was stored in 1 ml vials at −70° C. until required. The concentration of total cholesterol and triglycerides were determined using Sigma kits.
- Results
TABLE 8 Body Mass Index (kg/m2). Values are means ± sem. D0 D7 D15 D30 D60 D90 D120 D150 D180 D210 Control 30.61 ± 30.61 ± 29.41 ± 29.21 ± 29.03 ± 29.03 ± 2.34 30.04 ± 1.67 29.87 ± .98 29.22 ± 2.10 28.69 ± 3.01 2.03 2.03 2.42 1.68 1.76 Chitosan 28.66 ± 28.60 ± 27.31 ± 26.02 ± 26.03 ± 25.34 ± 1.67 27.87 ± 1.87 28.02 ± 1.67 26.21 ± 2.02 26.04 ± 1.53 1.78 1.78 2.02 2.01 1.67 Chitosan + 29.92 ± 29.83 ± 28.33 ± 26.18 ± 25.87 ± 25.34 ± 1.56* 25.02 ± 1.78* 24.98 ± 1.82* 25.38 ± 1.56* 24.88 ± 1.67* Vernonia 2.17 2.18 1.67 1.78 1.23* glabra Chitosan + cissus 28.43 ± 28.62 ± 28.04 ± 26.44 ± 24.64 ± 23.40 ± 2.68** 23.55 ± 2.67** 25.60 ± 3.56 24.36 ± 1.78* 24.31 ± 1.50* quadrangularis 1.53 1.33 1.89 0.98 1.22**
*p ≦ 0.05;
**p ≦ 0.01
- Conclusions:
- Subjects on a daily average energy intake of approximately 1500 kcal did not show any significant change in BMI. Subjects on the formulations containing Vernonia glabra as well as Cissus quadrangularis had reduced BMIs after being on the formulation for 60 days.
TABLE 9 Body fat content (%) D0 D7 D15 D30 D60 D90 D120 D150 D180 D210 Control 39 ± 9 41 ± 12 39 ± 14 37 ± 12 39 ± 6 37 ± 5 38 ± 8 36 ± 6 38 ± 6 36 ± 6 (37 ± 8) (35 ± 4) (33 ± 3) (32 ± 2) (31 ± 3) Chitosan 37 ± 10 38 ± 8 38 ± 6 35 ± 9 34 ± 7 34 ± 6 32 ± 3 35 ± 8 33 ± 6 33 ± 5 (36 ± 8) (33 ± 2) (31 ± 2) (31 ± 2) (29 ± 2) Chitosan + 36 ± 9 37 ± 10 36 ± 12 34 ± 8 31 ± 9 29 ± 10 29 ± 8 28 ± 8* 28 ± 8* 28 ± 9 Vernonia glabra (36 ± 6) (32 ± 3) (30 ± 2) (27 ± 2) (25 ± 3) (24 ± 3) Chitosan + cissus 37 ± 8 37 ± 8 36 ± 9 33 ± 8 29 ± 8 24 ± 9** 24 ± 6** 24 ± 7** 23 ± 4** 24 ± 5** quadrangularis (35 ± 4) (32 ± 2) (29 ± 3) (25 ± 3) (22 ± 2) (21 ± 2)
*p ≦ 0.05;
**p ≦ 0.01
(The figures in brackets represent values for subjects who were on a daily energy intake of 800 kcal rather than 1500 kcal.)
- Conclusion
- There is a significant decrease in total body fat in the groups treated with the chitosan formulations in subjects maintained on a diet of 1500 kcal per day. In subjects maintained on an 800 kcal per day diet, a decrease in body fat was observed in all groups.
TABLE 10 Total blood cholesterol (g/L) Day 0Day 7 Day 15 Day 30Day 60 Control 1.70 ± 0.12 1.50 ± 0.09 1.54 ± 0.18 1.65 ± 0.15 1.58 ± 0.11 Chitosan 1.60 ± 0.06 1.44 ± 0.10 0.73 ± 0.06** 0.92 ± 0.05** 0.84 ± 0.12** Chitosan + vernonia 2.07 ± 0.11 1.78 ± 0.10 1.42 ± 0.08 1.37 ± 0.11 1.23 ± 0.30* glabra Chitosan + cissus 1.94 ± 0.14 1.19 ± 0.18 0.85 ± 0.09** 0.81 ± 0.09** 1.01 ± 0.11** quadrangularis
*p ≦ 0.05;
**p ≦ 0.01
Significant differences are determined by comparing to the control for each time point.
- Conclusion
- Chitosan and the chitosan formulation containing Cissus quadrangularis were the most effective in lowering blood cholesterol levels for any given time point.
- Considering the composition of the formulations containing the plant extracts, it is obvious that there is a component in Vernonia glabra that inhibits the reduction of blood cholesterol levels by chitosan. On the other hand, a component or components present in Cissus quadrangularis may potentate this reduction.
TABLE 11 Total blood triglycerides (g/L) Day 0Day 7 Day 15 Day 30Day 60 Control 1.84 ± 0.08 1.83 ± 0.08 1.76 ± 0.10 1.89 ± 0.09 1.76 ± 0.18 Chitosan 1.26 ± 0.13 1.18 ± 0.05 0.65 ± 0.14** 0.83 ± 0.11* 0.74 ± 0.10** Chitosan + 1.87 ± 0.31 1.19 ± 0.08* 0.82 ± 0.09** 0.73 ± 0.06** 0.68 ± 0.08** vernonia glabra Chitosan + 1.84 ± 0.32 1.49 ± 0.27 0.62 ± 0.14** 0.84 ± 0.07** 0.70 ± 0.10** cissus quadrangularis
*p ≦ 0.05;
**p ≦ 0.01
Significant differences are determined by comparing to the control for each time point.
- Conclusion
- Chitosan and chitosan formulations significantly decreased the circulating concentrations of triglycerides. This is as a result of their ability to bind triglycerides in vitro as well as in vivo. The presence of plant extracts did not seem to have a potentiating effect on the ability of chitosan to bind triglycerides.
- The effect of Cissus quadrangularis and Vernonia glabra combination on blood lipid levels.
- The mixture used in this part of the work had the following composition:
Chitosan 61.8% Vitamin C 19.0% Vernonia glabra powder 5.7% Cissus quadrangularis powder 13.5% - This mixture had a superior lipid binding capacity in vitro compared to other chitosan formulations containing either Vernonia glabra or Cissus quadrangularis.
- In vitro Lipid Binding Capacity of Mixture
- 32.6 grams oleic acid per gram of mixture.
- Effect of Mixture on BMI in Overweight Adults (BMI>25)
- Body Mass Index (kg/m2)
- Values are means±sem.
TABLE 12 D0 D7 D15 D30 D60 D90 D120 D150 D180 D210 Control 30.61 ± 31.61 ± 29.41 ± 29.21 ± 29.03 ± 29.03 ± 2.34 30.04 ± 1.67 29.87 ± 1.98 29.22 ± 2.10 28.69 ± 3.01 2.03 2.03 2.42 1.68 1.76 Chitosan 28.66 ± 28.60 ± 27.31 ± 27.02 ± 26.03 ± 28.04 ± 27.87 ± 1.87 28.02 ± 1.67 26.21 ± 2.02 26.04 ± 1.53* 1.78 1.78 2.02 2.01 1.67 1.67 Chitosan + 29.92 ± 29.83 ± 23.33 ± 26.18 ± 25.87 ± 25.34 ± 1.56* 25.02 ± 1.78* 24.98 ± 1.82* 25.38 ± 1.56* 24.88 ± 1.67* Vernonia 2.17 2.18 1.67 1.78 1.23* glabra Chitosan + 28.43 ± 28.62 ± 28.04 ± 26.44 ± 24.64 ± 23.40 ± 2.68** 23.55 ± 2.67** 25.60 ± 3.56 24.36 ± 1.78* 24.31 ± 1.50* cissus 1.53 1.33 1.89 0.98 1.22** quadrangularis Chitosan + 28.71 ± 26.83 ± 25.40 ± 23.48 ± 23.47 ± 24.06 ± 1.33** 23.02 ± 0.78** 23.98 ± 1.82* Cissus/Vernonia 2.17 1.38 1.43 1.28** 1.22** mixture
*p ≦ 0.05;
**p ≦ 0.01
- The chitosan formulation containing a mixture of Cissus quadrangularis and Vernonia glabra significantly reduced the BMI of overweight females faster than formulations containing either Cissus quadrangularis or Vernonia glabra. This synergistic effect is possibly as a result of a reduction in the available glucose substrate for use as a fuel (α-amylase inhibition by Vernonia glabra). Fat preferentially used as fuel.
- The preferred specific mixture within the scope of the invention, has application because of its effects upon different physiological processes. Examples of preferred applications include the following:
- 1) Use in the management of obesity, overweight, weight maintenance, slowing down the addition of weight, reduction of bounce back during weight loss and complications resulting from obesity.
- This includes conditions such as hyperlipidemia, hypercholesteremia and, inability to move freely.
- 2) Uses in the management of diabetes and complications resulting from diabetes. This includes hyperglycemia, ketonuria and diabetic coma.
- 3) Use in controlling gastric acidosis.
- 4) Use in the relief of constipation.
- The above physiological processes are apparently brought about by action of the mixture on one or more of the following factors:
- Reduction of fat absorbed by the body; Increases in the amount of fat in feces increase of fecal bulk;
- Reduction of carbohydrate breakdown in vivo;
- Decrease in acidity of the stomach;
- Increase in the amount of cholesterol in the feces;
- Reduction of post-prandial blood glucose; and/or
- Reduction of Body mass index (BMI) and weight.
- Inhibition of Salivary and Pancreatic Amylase Activity
- Human salivary amylase (Sigma A0521) and porcine pancreatic amylase (Sigma A3176) were used as starting material. The substrate used was starch and the formation of maltose was used to quantify and measure the activity of the amylase. One unit of activity of the mixture reduced the activity of salivary amylase by 50%, and the activity of pancreatic amylase by 65%.
- Decrease of Acidity of the Stomach
- Laboratory animals were fed diets containing the mixture (0.5 ml/kg body weight) after an overnight fast.
- The content of their stomachs had a higher pH than control animals.
- Humans who ingested the mixture produced feces with a lower pH than control humans who had not ingested the mixture.
- Inhibition of Pancreatic Lipase Activity
- Pancreatic Lipase (Sigma L9780) was used as starting material.
- One unit of the mixture is the quantity that will reduce the activity of 0.48 units of lipase by 50%. (One unit of lipase will liberate 1.0 μl of 2-monoglyceride from 1,2-diglyceride per minute at 37° C., pH 8.1).
- While the apparatus and method have been described in terms of what are presently considered to be the most practical and preferred embodiments, it is to be understood that the disclosure need not be limited to the disclosed embodiments. It is intended to cover various modifications and similar arrangements included within the spirit and scope of the claims, the scope of which should be accorded the broadest interpretation so as to encompass all such modifications and similar structures. The present disclosure includes any and all embodiments of the following claims.
Claims (4)
1-26. (canceled)
27. A composition comprising at least one extract from one or more plants selected from one or more of the plant families: Cissus, Brillantaisia and Vernonia, together with one or more amylase inhibiting compounds.
28. A composition as claimed in claim 27 wherein each extract is of one or more of the following plant families: Cissus sp., Brillantaisia sp. and Vernonia sp.
29. A composition as claimed in claim 28 wherein the extract is Cissus sp.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/464,469 US20070190185A1 (en) | 1999-08-27 | 2006-08-14 | Plant extract mixtures and their uses |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9920393.7 | 1999-08-27 | ||
GBGB9920393.7A GB9920393D0 (en) | 1999-08-27 | 1999-08-27 | Plant extract mixtures and their uses |
PCT/GB2000/003324 WO2001015716A1 (en) | 1999-08-27 | 2000-08-29 | Plant extract mixtures and their uses |
US10/069,743 US7175859B1 (en) | 1999-08-27 | 2000-08-29 | Plant extract mixtures and their uses |
US11/464,469 US20070190185A1 (en) | 1999-08-27 | 2006-08-14 | Plant extract mixtures and their uses |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/069,743 Continuation US7175859B1 (en) | 1999-08-27 | 2000-08-29 | Plant extract mixtures and their uses |
PCT/GB2000/003324 Continuation WO2001015716A1 (en) | 1999-08-27 | 2000-08-29 | Plant extract mixtures and their uses |
Publications (1)
Publication Number | Publication Date |
---|---|
US20070190185A1 true US20070190185A1 (en) | 2007-08-16 |
Family
ID=10859982
Family Applications (7)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/069,743 Expired - Lifetime US7175859B1 (en) | 1999-08-27 | 2000-08-29 | Plant extract mixtures and their uses |
US11/464,466 Expired - Lifetime US7736675B2 (en) | 1999-08-27 | 2006-08-14 | Plant extract mixtures and their uses |
US11/464,469 Abandoned US20070190185A1 (en) | 1999-08-27 | 2006-08-14 | Plant extract mixtures and their uses |
US11/464,471 Expired - Lifetime US7695742B2 (en) | 1999-08-27 | 2006-08-14 | Plant extract mixtures and their uses |
US11/464,474 Expired - Lifetime US7718200B2 (en) | 1999-08-27 | 2006-08-14 | Plant extract mixtures and their uses |
US12/504,327 Expired - Lifetime US8318213B2 (en) | 1999-08-27 | 2009-07-16 | Plant extract mixtures and their uses |
US12/504,257 Abandoned US20090274784A1 (en) | 1999-08-27 | 2009-07-16 | Plant extract mixtures and their uses |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/069,743 Expired - Lifetime US7175859B1 (en) | 1999-08-27 | 2000-08-29 | Plant extract mixtures and their uses |
US11/464,466 Expired - Lifetime US7736675B2 (en) | 1999-08-27 | 2006-08-14 | Plant extract mixtures and their uses |
Family Applications After (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/464,471 Expired - Lifetime US7695742B2 (en) | 1999-08-27 | 2006-08-14 | Plant extract mixtures and their uses |
US11/464,474 Expired - Lifetime US7718200B2 (en) | 1999-08-27 | 2006-08-14 | Plant extract mixtures and their uses |
US12/504,327 Expired - Lifetime US8318213B2 (en) | 1999-08-27 | 2009-07-16 | Plant extract mixtures and their uses |
US12/504,257 Abandoned US20090274784A1 (en) | 1999-08-27 | 2009-07-16 | Plant extract mixtures and their uses |
Country Status (12)
Country | Link |
---|---|
US (7) | US7175859B1 (en) |
EP (1) | EP1212070B1 (en) |
JP (1) | JP2003508444A (en) |
CN (1) | CN1384750A (en) |
AT (1) | ATE342726T1 (en) |
AU (1) | AU782646B2 (en) |
BR (1) | BR0014152A (en) |
CA (1) | CA2382551A1 (en) |
DE (1) | DE60031421T2 (en) |
GB (1) | GB9920393D0 (en) |
WO (1) | WO2001015716A1 (en) |
ZA (1) | ZA200201856B (en) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4549486B2 (en) * | 2000-04-26 | 2010-09-22 | アピ株式会社 | Anti-obesity drug and method for producing the same |
JP3839832B2 (en) * | 2005-03-29 | 2006-11-01 | 弘道 山下 | Appetite suppressant and diet air conditioner |
US7582316B1 (en) * | 2005-07-21 | 2009-09-01 | Jacob Geissler | Ketone-steroid extracts from the Cissus Quadrangularis plant and methods thereof |
US20070196515A1 (en) * | 2006-02-22 | 2007-08-23 | Kothari Shil C | Methods and compositions for improving cardiovascular risk factors and metabolic risk factors that cause syndrome X |
AU2007341056A1 (en) * | 2006-07-07 | 2008-07-10 | Avestha, Gengraine, Technologies, Pvt., Ltd. | Cissus quadrangularis plant extracts for treating osteoporosis and the extraction process thereof |
WO2008028268A1 (en) * | 2006-09-08 | 2008-03-13 | Multi Formulations Ltd. | Diet supplement for causing weight loss comprising cissus quandrangulans, green tea and caffeine |
US20080166419A1 (en) * | 2007-01-04 | 2008-07-10 | Sones Scott F | Krill oil compositions |
WO2008124105A1 (en) * | 2007-04-04 | 2008-10-16 | Naturegen, Inc. | Compositions and methods for obesity, diabetes and metabolic syndrome control and management |
JP5543329B2 (en) * | 2007-04-17 | 2014-07-09 | バイエル・コンシューマー・ケア・アクチェンゲゼルシャフト | Use of Vernonia extract |
US20080279967A1 (en) * | 2007-05-10 | 2008-11-13 | Marvin Heuer | Composition and method for increasing the metabolism of free fatty acids and facilitating a favorable blood lipid |
WO2009076742A1 (en) * | 2007-12-18 | 2009-06-25 | Multi Formulations Ltd. | Effervescent dietary composition for enhancing delivery of dietary ingredients |
CN102151293B (en) * | 2011-03-31 | 2012-07-25 | 浙江农林大学 | Preparation method of plant extractive and use |
WO2013018103A2 (en) | 2011-08-04 | 2013-02-07 | Ramaswamy Rajendran | Extraction of b-vitamins from plant matter |
US8647685B1 (en) | 2012-08-03 | 2014-02-11 | Timing Pharmaceutical Co., Ltd. | Composite of herbal extracts for lowering blood lipid and medication comprising the said composite |
JP7062433B2 (en) * | 2017-12-20 | 2022-05-06 | 株式会社ファンケル | Composition for reducing blood uric acid level containing chitosan and ampelopsin |
KR102292060B1 (en) * | 2019-11-26 | 2021-08-19 | 유동술 | Composition comprising of the combined extract of Cissus verticillata and Cyclopia Intermedia as an active ingredient for preventing or treating obesity |
KR102292059B1 (en) * | 2019-11-26 | 2021-08-19 | 유동술 | Composition comprising of the extract of Cissus verticillata and Cyclopia Intermedia as an active ingredient for preventing or treating diabetic complication and diabetes |
WO2022221177A1 (en) * | 2021-04-11 | 2022-10-20 | Khurana Vikas | Diagnosis and treatment of congestive colon failure (ccf) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5894070A (en) * | 1994-07-19 | 1999-04-13 | Astra Aktiebolag | Hard tissue stimulating agent |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3368903A (en) * | 1966-02-18 | 1968-02-13 | Vanderbilt Co R T | Baked goods dough and method |
US5278176A (en) | 1992-08-21 | 1994-01-11 | Abbott Laboratories | Nicotine derivatives that enhance cognitive function |
JPH0725761A (en) | 1993-07-09 | 1995-01-27 | Kureha Chem Ind Co Ltd | Agent for protecting cartilage |
JPH09194392A (en) | 1996-01-18 | 1997-07-29 | Nisshin Flour Milling Co Ltd | Amylase inhibitor |
US5736532A (en) * | 1996-02-14 | 1998-04-07 | Furda; Ivan | Multifunctional fat absorption and blood cholesterol reducing formulation comprising chitosan |
JPH10182469A (en) * | 1996-12-26 | 1998-07-07 | Sanin Kensetsu Kogyo Kk | Cerebral apoplexy preventing or treating agent |
JPH1150050A (en) * | 1997-08-06 | 1999-02-23 | Lion Corp | Antioxidant |
DE10142722A1 (en) | 2001-08-31 | 2003-03-27 | Aventis Pharma Deutschland GmbH, 65929 Frankfurt | C2-substituted indan-1-ones and their derivatives, processes for their preparation and their use as medicaments |
WO2003105766A2 (en) | 2002-06-12 | 2003-12-24 | University Of Virginia Patent Foundation | Rsk inhibitors and therapeutic uses thereof |
US20050084547A1 (en) * | 2003-09-12 | 2005-04-21 | Phytomyco Research Corporation | Natural product based apoptosis inducers |
-
1999
- 1999-08-27 GB GBGB9920393.7A patent/GB9920393D0/en not_active Ceased
-
2000
- 2000-08-29 WO PCT/GB2000/003324 patent/WO2001015716A1/en active IP Right Grant
- 2000-08-29 EP EP00956678A patent/EP1212070B1/en not_active Expired - Lifetime
- 2000-08-29 US US10/069,743 patent/US7175859B1/en not_active Expired - Lifetime
- 2000-08-29 JP JP2001519929A patent/JP2003508444A/en active Pending
- 2000-08-29 CA CA002382551A patent/CA2382551A1/en not_active Abandoned
- 2000-08-29 AU AU68547/00A patent/AU782646B2/en not_active Ceased
- 2000-08-29 CN CN00814998A patent/CN1384750A/en active Pending
- 2000-08-29 BR BR0014152-6A patent/BR0014152A/en not_active Application Discontinuation
- 2000-08-29 AT AT00956678T patent/ATE342726T1/en not_active IP Right Cessation
- 2000-08-29 DE DE60031421T patent/DE60031421T2/en not_active Expired - Fee Related
-
2002
- 2002-03-06 ZA ZA200201856A patent/ZA200201856B/en unknown
-
2006
- 2006-08-14 US US11/464,466 patent/US7736675B2/en not_active Expired - Lifetime
- 2006-08-14 US US11/464,469 patent/US20070190185A1/en not_active Abandoned
- 2006-08-14 US US11/464,471 patent/US7695742B2/en not_active Expired - Lifetime
- 2006-08-14 US US11/464,474 patent/US7718200B2/en not_active Expired - Lifetime
-
2009
- 2009-07-16 US US12/504,327 patent/US8318213B2/en not_active Expired - Lifetime
- 2009-07-16 US US12/504,257 patent/US20090274784A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5894070A (en) * | 1994-07-19 | 1999-04-13 | Astra Aktiebolag | Hard tissue stimulating agent |
Also Published As
Publication number | Publication date |
---|---|
AU6854700A (en) | 2001-03-26 |
US20090324758A1 (en) | 2009-12-31 |
DE60031421T2 (en) | 2007-08-23 |
AU782646B2 (en) | 2005-08-18 |
ZA200201856B (en) | 2002-12-24 |
CN1384750A (en) | 2002-12-11 |
US20070202196A1 (en) | 2007-08-30 |
EP1212070A1 (en) | 2002-06-12 |
US8318213B2 (en) | 2012-11-27 |
ATE342726T1 (en) | 2006-11-15 |
US7736675B2 (en) | 2010-06-15 |
CA2382551A1 (en) | 2001-03-08 |
GB9920393D0 (en) | 1999-11-03 |
US7718200B2 (en) | 2010-05-18 |
EP1212070B1 (en) | 2006-10-18 |
US7175859B1 (en) | 2007-02-13 |
US7695742B2 (en) | 2010-04-13 |
WO2001015716A1 (en) | 2001-03-08 |
DE60031421D1 (en) | 2006-11-30 |
JP2003508444A (en) | 2003-03-04 |
US20090274784A1 (en) | 2009-11-05 |
BR0014152A (en) | 2002-05-14 |
US20070202204A1 (en) | 2007-08-30 |
US20070048392A1 (en) | 2007-03-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7695742B2 (en) | Plant extract mixtures and their uses | |
CN102406860B (en) | Composition for preventing and treating diabetes, and preparation method and use thereof | |
US8318218B2 (en) | Composition comprising 1,3/1, 6 beta glucan for reducing weight | |
US5932561A (en) | Dietary composition with lipid binding properties for weight management and serum lipid reduction | |
IL92098A (en) | Glucan dietary additives | |
NZ569750A (en) | Therapeutic agent for metabolic syndrome and food containing the therapeutic agent | |
Han et al. | Resistant starches of beans reduce the serum cholesterol concentration in rats | |
US20120156185A1 (en) | Nutritional compositions comprising citrus fibers | |
Baba et al. | Fructooligosaccharides stimulate the absorption of magnesium from the hindgut in rats | |
EP1371368A1 (en) | Salvianolic acid components as lipase inhibitors | |
Elliott et al. | Effects of tomato pomace and mixed-vegetable pomace on serum and liver cholesterol in rats | |
KR100314999B1 (en) | Herbal Medicine for the Treatment of Antibacterial and Inflammatory Diseases | |
KR100315000B1 (en) | Herbal Herbs Treatment for Hyperlipidemia Containing Enteric Bellflower Extract | |
KR100315001B1 (en) | Herbal Medicine for the Treatment of Diabetes Mellitus Containing Enteric Bellflower Extract | |
US5773426A (en) | Proteoglucan and antidiabetic drug thereof | |
KR100532556B1 (en) | Composition for treating obesity and constipation containing extract of pine needle, green tea and black tea as an active ingredient | |
KR101373493B1 (en) | Composition comprising Hizikia fusiformis for preventing and treating obesity or hyperlipidemia and atherosclerotic-vascular diseases | |
Jun et al. | Anti-obesity effects of chitosan and psyllium husk with L-ascorbic acid in guinea pigs | |
KR100450055B1 (en) | Food composition for improving physical constitution containing seeds of bean plants as main components, and food produced therefrom | |
Abdalla et al. | Evaluation Anti-Obesity Activity of Psyllium Seeds Powder on Rats Fed a High Fat Diet | |
Phytomed | In vitro bile acid sequestering properties of Morus indica L. leaves | |
ITRM960279A1 (en) | USE OF DIETARY SUPPLEMENT INCLUDING CHITOSAN, HYDROXYCITRATE OF GARCINIA, CAMBODIA AND ORGANIC CHROMIUM IN THE TREATMENT OF DISLIPI = | |
Trepel | Ballaststoffe: Mehr als ein Diätmittel. | |
WO2010083937A1 (en) | Use of plant extracts comprising polyphenol for treating adiposity and diabetes mellitus type 2 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |